(SENS) Senseonics Holdings - Ratings and Ratios
Implantable, Glucose, Sensor, Transmitter, App
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 66.8% |
| Value at Risk 5%th | 95.4% |
| Relative Tail Risk | -13.24% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.13 |
| Alpha | -57.58 |
| CAGR/Max DD | -0.40 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.516 |
| Beta | 1.557 |
| Beta Downside | 0.964 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.89% |
| Mean DD | 53.60% |
| Median DD | 57.85% |
Description: SENS Senseonics Holdings October 25, 2025
Senseonics Holdings, Inc. (NYSE MKT:SENS) is a commercial-stage medical-technology firm that designs, manufactures, and markets implantable continuous glucose monitoring (CGM) systems-including the Eversense, Eversense XL, Eversense E3, and Eversense 365-for diabetes patients in the United States and abroad. The platform combines a sub-cutaneous sensor, a rechargeable smart transmitter, and a mobile app to deliver real-time glucose data, and the company distributes its products through a network of medical distributors and fulfillment partners. Founded in 1996, Senseonics is headquartered in Germantown, Maryland.
Key quantitative signals as of the latest quarter (Q2 2025) include: • Revenue of $22 million, reflecting a 38 % year-over-year increase driven primarily by the launch of the Eversense 365 system in the U.S. market; • Cash and cash equivalents of $115 million, providing roughly 12 months of runway at current burn rates; • A 15 % market-share capture in the long-duration CGM niche, where the overall CGM market is projected to grow at a 12 % CAGR through 2030, powered by rising diabetes prevalence and reimbursement expansions. The sector’s growth is also sensitive to FDA regulatory outcomes and payer coverage decisions, which remain primary catalysts for Senseonics’ near-term performance.
For a deeper, data-driven view of how Senseonics’ fundamentals stack up against peers, you might explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-64.7m TTM) > 0 and > 6% of Revenue (6% = 1.86m TTM) |
| FCFTA -0.40 (>2.0%) and ΔFCFTA 25.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 356.1% (prev 235.0%; Δ 121.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.40 (>3.0%) and CFO -55.4m > Net Income -64.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (45.0m) change vs 12m ago 44.80% (target <= -2.0% for YES) |
| Gross Margin 41.60% (prev -10.49%; Δ 52.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 26.20% (prev 23.05%; Δ 3.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -8.33 (EBITDA TTM -55.5m / Interest Expense TTM 6.94m) >= 6 (WARN >= 3) |
Altman Z'' -38.26
| (A) 0.79 = (Total Current Assets 131.3m - Total Current Liabilities 21.1m) / Total Assets 139.9m |
| (B) -7.12 = Retained Earnings (Balance) -996.2m / Total Assets 139.9m |
| warn (B) unusual magnitude: -7.12 — check mapping/units |
| (C) -0.49 = EBIT TTM -57.8m / Avg Total Assets 118.1m |
| (D) -16.13 = Book Value of Equity -996.0m / Total Liabilities 61.8m |
| Total Rating: -38.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.92
| 1. Piotroski 1.0pt |
| 2. FCF Yield -31.43% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.53 |
| 5. Debt/Ebitda -0.12 |
| 6. ROIC - WACC (= -62.31)% |
| 7. RoE -135.2% |
| 8. Rev. Trend 73.70% |
| 9. EPS Trend -49.39% |
What is the price of SENS shares?
Over the past week, the price has changed by -6.65%, over one month by +12.77%, over three months by -32.97% and over the past year by -34.67%.
Is SENS a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the SENS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.9 | 206.1% |
| Analysts Target Price | 18.9 | 206.1% |
| ValueRay Target Price | 4.4 | -28.5% |
SENS Fundamental Data Overview December 19, 2025
P/E Forward = 21.5054
P/S = 8.493
P/B = 3.4578
Beta = 0.929
Revenue TTM = 30.9m USD
EBIT TTM = -57.8m USD
EBITDA TTM = -55.5m USD
Long Term Debt = 35.3m USD (from longTermDebt, last quarter)
Short Term Debt = 479.0k USD (from shortTermDebt, last quarter)
Debt = 41.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.39m USD (from netDebt column, last quarter)
Enterprise Value = 178.7m USD (248.8m + Debt 41.2m - CCE 111.3m)
Interest Coverage Ratio = -8.33 (Ebit TTM -57.8m / Interest Expense TTM 6.94m)
FCF Yield = -31.43% (FCF TTM -56.2m / Enterprise Value 178.7m)
FCF Margin = -181.5% (FCF TTM -56.2m / Revenue TTM 30.9m)
Net Margin = -209.2% (Net Income TTM -64.7m / Revenue TTM 30.9m)
Gross Margin = 41.60% ((Revenue TTM 30.9m - Cost of Revenue TTM 18.1m) / Revenue TTM)
Gross Margin QoQ = 42.84% (prev 47.62%)
Tobins Q-Ratio = 1.28 (Enterprise Value 178.7m / Total Assets 139.9m)
Interest Expense / Debt = 2.84% (Interest Expense 1.17m / Debt 41.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -45.7m (EBIT -57.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.23 (Total Current Assets 131.3m / Total Current Liabilities 21.1m)
Debt / Equity = 0.53 (Debt 41.2m / totalStockholderEquity, last quarter 78.2m)
Debt / EBITDA = -0.12 (negative EBITDA) (Net Debt 6.39m / EBITDA -55.5m)
Debt / FCF = -0.11 (negative FCF - burning cash) (Net Debt 6.39m / FCF TTM -56.2m)
Total Stockholder Equity = 47.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.27% (Net Income -64.7m / Total Assets 139.9m)
RoE = -135.2% (Net Income TTM -64.7m / Total Stockholder Equity 47.9m)
RoCE = -69.51% (EBIT -57.8m / Capital Employed (Equity 47.9m + L.T.Debt 35.3m))
RoIC = -51.91% (negative operating profit) (NOPAT -45.7m / Invested Capital 88.0m)
WACC = 10.40% (E(248.8m)/V(290.0m) * Re(11.75%) + D(41.2m)/V(290.0m) * Rd(2.84%) * (1-Tc(0.21)))
Discount Rate = 11.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 30.20%
Fair Price DCF = unknown (Cash Flow -56.2m)
EPS Correlation: -49.39 | EPS CAGR: -76.10% | SUE: -4.0 | # QB: 0
Revenue Correlation: 73.70 | Revenue CAGR: 20.62% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.51 | Chg30d=-0.130 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=-2.19 | Chg30d=-0.665 | Revisions Net=-1 | Growth EPS=-41.4% | Growth Revenue=+71.2%
Additional Sources for SENS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle